Recent Updates
Recently added Catalysts
ALVO

Alvotech publishes prospectus related to the admission to trading and listing on Nasdaq Iceland Main Market

Key Takeaway: Alvotech publishes prospectus related to the admission to trading and listing on Nasdaq Iceland Main Market Reference is made to the announcement issued on December 2, 2022 confirming that Nasdaq Iceland has approved Alvotech S.A s ( Alvotech ) request for admission to trading
Price reaction · baseline $6.56 (2022-12-05 close) · hit after-hours · 2 other ALVO headline(s) in the window, move may be shared
day 0 close · peak
+4.9%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
13.8%
average across 7 past catalysts
Lead asset
Stelara
Phase 3 · Psoriasis

Full Press Release Details

Alvotech publishes prospectus related to the admission to trading and listing on Nasdaq Iceland Main Market
Reference is made to the announcement
issued on December 2, 2022 confirming that Nasdaq Iceland has approved Alvotech S.A s ( Alvotech ) request for admission to trading of its shares on the Nasdaq Iceland Main Market ( Main Market ), pending
passporting of the prospectus to Iceland.
The prospectus has now been approved by the Commission de Surveillance du Secteur Financier, 283 route
d Arion-L2991 Luxembourg ( CSSF ) and passported to Iceland. It is accessible on Alvotech s website at https://investors.alvotech.com/prospectus.
Nasdaq Iceland will announce the first day of trading with at least one day advance notice.
Landsbankinn Corporate Banking provided process oversight for the transfer of the listing of Alvotech s shares to the Main Market and admission to
Alvotech Investor Relations and Global Communication
alvotech.ir[at]alvotech.com
Last updated: Dec 6, 2022